Clinical Evidence in Asian Indian Patients The Indian thin fat phenotype is more prone to the development of T2DM and is associated with several unique features, such as early age of T2DM onset, early decline in beta cell mass, higher insulin resistance, higher carbohydrate intake and physical inactivity leading to central obesity, unique dyslipidemia pattern, increased CV disease risk, higher association with nonalcoholic fatty liver disease, among others [29,30,31]
Retatrutide is an investigational triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved agents such as semaglutide or tirzepatide
Nature Medicine asks leading researchers to name their top clinical trial for 2025, from gene therapies for prion disease and sickle-cell disease to digital tools for cancer and mental health
P.et al (1995)
Man vet inte hur lngt han r beredd p att g, sger Fouad Youcefi, USA-korrespondent.Mer om programmet Hur mycket dyrare har maten blivit p tv och ett halvt r
When to Speak with Your GP About GLP-1 and Breastfeeding Proactive communication with your GP or diabetes specialist team is essential if you are taking or considering GLP-1 medications whilst breastfeeding or planning to breastfeed
